Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2940 • 2014 ACR/ARHP Annual Meeting
Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? – a Prospective Study Including Magnetic Resonance Imaging
Xenofon Baraliakos¹, Uta Kiltz¹, Frank Heldmann¹, Heiner Appel², Friedrich Dybowski³, Manfred Igelmann⁴, Ludwig Kalthoff⁵, Dietmar Krause⁶, Hans-Jürgen Menne⁷, Ertan Saracbasi⁸, Elmar Schmitz-Bortz⁹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology and Nephrology Practice, Hamm, Germany, ³Rheumatology Practice, Herne, Germany, ⁴Rheumatology Practice, Bochum, Germany, ⁵Rheumatology practice, Herne, Germany, ⁶Rheumatology practice, Gladbeck, Germany, ⁷Rheumatology practice, Dortmund, Germany, ⁸Rheumatology practice, Oberhausen, Germany, ⁹Rheumatology practice, Hattingen, Germany
Background/Purpose: Patients classified as axial spondyloarthritis (axSpA) may have ankylosing spondylitis (AS) or non-radiographic axSpA (nr-axSpA). Treatment recommendations for AS consider non-steroidal anti-inflammatory drugs (NSAIDs)…
Abstract Number: 2590 • 2014 ACR/ARHP Annual Meeting
Comparison of Radiographic Damage Score in Ankylosing Spondylitis According to Tumor Necrosis Factor Inhibitor: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) Data
Tae-Jong Kim¹, JI Hui SHIN², Il-Hoon Sung³, Seunghun Lee⁴, Kyung-Bin Joo⁵ and Tae-Hwan Kim⁶, ¹Chonnam Nat`l University Medical School&Hospital, Gwangju, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Department of Radiology, Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Department of Radiology, Department of Radiology, Hanynag University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose To evaluate the influence of tumor necrosis factor (TNF) blocker on the radiographic damage in ankylosing spondylitis (AS). Methods . A total of 610…
Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
Abstract Number: 597 • 2014 ACR/ARHP Annual Meeting
Inflammatory Burden in Recent-Onset Axial Spondyloarthritis
Juan Jose Aznar Sánchez¹, Raul Veroz Gonzalez¹, Adela Gallego Flores¹, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain
Background/Purpose Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don't presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured…
Abstract Number: 568 • 2014 ACR/ARHP Annual Meeting
Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Susana Holgado¹, Maria Lourdes Mateo¹, Juana Sanint¹, Anne Riveros-Frutos², Jeronima Cañellas¹, Xavier Tena¹ and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Secondary amyloidosis (AA) is a disorder caused by deposition of insoluble amyloid A fibrils in different tissues and organs. It is a rare and…
Abstract Number: 2827 • 2014 ACR/ARHP Annual Meeting
Cervical Spine Fracture and Mortality in Ankylosing Spondylitis
Katherine D. Wysham¹, Sara G. Murray², Nancy K. Hills³, Edward H. Yelin⁴ and Lianne S. Gensler⁵, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Little data exist regarding mortality in Ankylosing Spondylitis (AS) patients. We performed a population-based study of diagnoses associated with hospital mortality in AS. Methods:…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
Abstract Number: 596 • 2014 ACR/ARHP Annual Meeting
Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis
Agusti Sellas-Fernandez¹, Jose Luis Guerra Vázquez², Jose Luis Casals³, Carlos Gonzalez Fernandez⁴, Roberto Miguelez⁵, José Rosas⁶, Antonio Fernandez-Nebro⁷, Cilia Peralta Ginés⁸, Carlos Montilla-Morales⁹, Xavier Juanola¹⁰, Miguel Ángel Abad¹¹, Alberto Alonso¹², Azucena Hernández-Sanz¹³, Luis Francisco Linares¹⁴, Julio Medina¹⁵, Joana Rovira¹⁶, Juan Carlos Torre-Alonso¹⁷, Alfredo Willisch¹⁸, Eduardo Collantes-Estevez¹⁹ and Ana Ruiz-Zorrilla²⁰, ¹H. Vall d'Hebron, Barcelona, Spain, ²H. Arquitecto Marcide, La Coruña, Spain, ³H. Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵H. de Móstoles, Madrid, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Valencia, Alicante, Spain, ⁷Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁸H. Clínico Lozano Blesa, Zaragoza, Spain, ⁹H. de Salamanca, Salamanca, Spain, ¹⁰Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ¹¹Hospital Virgen del Puerto, Cáceres, Spain, ¹²Hospital de Cruces, Bilbao, Spain, ¹³H. Virgen de la Salud, Toledo, Spain, ¹⁴Hospital Virgen de la Arrixaca., Murcia, Spain, ¹⁵Hospital Clínico, Valladolid, Spain, ¹⁶Mutua Terrasa, Barcelona, Spain, ¹⁷Rheumatology Department, H. Monte Naranco, Oviedo, Spain, ¹⁸Complexo Hospitalario de Ourense, Ourense, Spain, ¹⁹Hospital Reina Sofía, Córdoba, Spain, ²⁰Abbvie, Madrid, Spain
Background/Purpose The ASDAS (ankylosing spondylitis disease activity score) was developed to overcome some of the deficiencies of BASDAI (Bath Ankylosing Disease Activity Spondyltis Index). In…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 595 • 2014 ACR/ARHP Annual Meeting
Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort
Concepcion Castillo-Gallego¹, Jesus Sanz², Carmen Martin-Hervas³, Mireia Moreno⁴, Victoria Navarro-Compán⁵, Diana Peiteado¹, Jorge Gratacos-Masmitja⁶, Eugenio De Miguel⁷ and Emilio Martín-Mola¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Radiology, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁵Rheumatology, Rheumatologist, Madrid, Spain, ⁶Parc Tauli, S/N, Hospital Parc Tauli, Sabadell, Spain, ⁷Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The current concept of axial Spondyloarhtritis (axSpA) considers non-radiographic axSpA (nr-axSpA) and Ankylosing Spondylitis (AS) as two stages of one disease. There are limited…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].